但这些激励措施为制药企业带来的收益远远超过了实际研发成本；于是成为让公共资金流入私人腰包的工具 — — 而恰恰是这些人最初造成了问题。
But the benefits of such incentives for pharmaceutical companies would far exceed the cost of the actual R&D pursued; they would be instruments to funnel public funds into private hands – the very hands that caused the problem.